Wrong assumption to think there could have been no issue with trial integrity. Any SOC/placebo patients then currently in the trial in any of the 4 countries they were enrolled in might have demanded to be crossed over early at a time when no ECA measures had been agreed upon in principle by the various regulators. Remember that more than half of trial participants were enrolled in 2014 to November 2015 which means that a significant group of placebo/SOC patients were still in the trial. That would have created an untenable situation and a big problem for determining actual quality life years benefit beyond this. That assumption is a non starter. Sharing the screening hold rational with investors would have unlocked the block on NWBO insiders from purchasing but also on others like Mr. Neil Woodford from trading on undisclosed information at a time when NWBO was at its most vulnerable financial position and could have been taken over very cheaply from Linda and supporting longs unable to match the dollars spent to do so or shorted into oblivion. Big picture stuff; ). Best wishes.
Market Data 
Markets 
AI
